Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
May 18, 2009
- Additional Indications to Be Approved for Nexavar, Valixa, Alimta
May 18, 2009
- Questions Raised on Approval of Caduet: CDFS
May 18, 2009
- Hospitals Should Not Use In-House Prescriptions to Obtain Yakkasa
May 18, 2009
- BUSINESS NEWS IN BRIEF
May 18, 2009
- Highlights of 97th JUA Annual Meeting
May 18, 2009
- IMS Proposes Shift of Focus to Emerging Markets
May 18, 2009
- Applied Therapeutics Society Inaugurated
May 18, 2009
- Alfresa to Reduce SGA Cost Ratio to 5-5.5%
May 18, 2009
- Survey Reveals Low Awareness Rates for OTC Drugs, Self-Medication
May 18, 2009
- Price Settlement Rate Stood at 98% as of the End of FY2008
May 18, 2009
- On-line Sale of Class 2 OTC Drugs to Be Permitted for 2 Years
May 18, 2009
- Torii: Sales Down 8.6% Due to Transfer of Stronger Neo Minophagen
May 18, 2009
- Taisho to Enter Market for Topical OTC NSAIDs with Diclotect
May 18, 2009
- Teijin Aims at ¥400 Bil. Sales for Drugs, Home Healthcare Business in 2020
May 18, 2009
- Novartis Launches Switch OTC Voltaren
May 18, 2009
- Merger Boosts Kyowa Kirin's Sales, Profits
May 18, 2009
- 18 APIs to Be Recommended as Switch OTC Drugs
May 18, 2009
- MTPC Aims at Restoring Public's Confidence, Developing Global Products: New President-elect Dr Tsuchiya
May 18, 2009
- NBI's Telmisartan + HCT Combinations Approved
May 4, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…